Vera Belaoussoff
Corporate Officer/Principal at CellAegis Devices, Inc.
Vera Belaoussoff active positions
| Companies | Position | Start | End |
|---|---|---|---|
CellAegis Devices, Inc.
 CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Corporate Officer/Principal | - | - |
Career history of Vera Belaoussoff
Former positions of Vera Belaoussoff
| Companies | Position | Start | End |
|---|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 08/10/2009 | - |
Training of Vera Belaoussoff
| York University | Graduate Degree |
| University of Manitoba | Undergraduate Degree |
Statistics
International
| Canada | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Electronic Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
CellAegis Devices, Inc.
CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Electronic Technology |
- Stock Market
- Insiders
- Vera Belaoussoff
- Experience